Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • About
    • Our Mission
    • Leadership
    • Board of Directors
  • Our Science
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us

News

Investors

Investors

  • Overview
  • Corporate Presentation
  • News
  • Events
  • Stock Quote and Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Info
Jun 27, 2023 4:05 pm EDT
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
May 11, 2023 4:05 pm EDT
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
Mar 23, 2023 4:50 pm EDT
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
Mar 8, 2023 7:00 am EST
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Feb 10, 2023 4:05 pm EST
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Dec 15, 2022 7:00 am EST
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
Nov 9, 2022 4:05 pm EST
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
Nov 1, 2022 7:00 am EDT
Rezolute to Present at the Jefferies London Healthcare Conference
Oct 20, 2022 7:00 am EDT
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
Sep 15, 2022 4:05 pm EDT
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 16
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
rezolute logo

©2025 Rezolute, Inc.

Explore

  • About
  • Approach
  • Pipeline
  • Publications
  • For Patients
  • Join Us
  • Investors & Media
  • Contact Us

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065

+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Oregon Office
2783 NW Lolo Drive
Suite 150
Bend, OR 97703

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Approach
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us